Drugs / Grafalon
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06744400 | Jan 2025 → Jan 2026 overdue | — | Centre Hospitalier Universitaire de Besancon | Not yet recruiting | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT04936282 | Jul 2022 → Jun 2027 expected | chronic transplant rejection | Canary Isles Institute for Health Research Foundation | Active not recruiting | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2/3 | NCT01949129 Background | Apr 2013 → Jun 2030 expected | acute lymphoblastic leukemia | St. Anna Children's Cancer Research | Recruiting | No outcome recorded |
| Phase 3 | NCT06083129 Comparator | Nov 2023 → Nov 2028 expected | graft versus host disease | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Grafalon | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04936282 ↗ |
| Action | Deplete | “They induce rapid depletion of immune cells, particularly T lymphocytes.” NCT06744400 ↗ |
| Modality | Protein / enzyme biologic | “Anti-T lymphocyte globulin (ATLG)” NCT06083129 ↗ |
| Route | Intravenous | “10 mg/Kg/day IV for 3 consecutive days (day-3 to -1 before transplantation)” NCT06083129 ↗ |